Omeros Reports Positive Data Using OMS721 In MASP-2 Program

(RTTNews) - Omeros Corp. (OMER), Tuesday announced positive data using OMS721, the lead human monoclonal antibody in Omeros' mannan-binding lectin-associated serine protease-2 or MASP-2 program, in a well-established animal model of neovascular age-related macular degeneration or AMD. The company said that it is currently completing a Phase 1 clinical trial of OMS721 in healthy subjects.

In July, Omeros began enrollment in its Phase 1 clinical program studying the safety, tolerability, pharmacodynamics and pharmacokinetics of OMS721 administered intravenously and subcutaneously in healthy subjects. A Phase 2 clinical trial in patients suffering from TMAs, including atypical hemolytic uremia syndrome, is planned to begin enrollment in early 2014.